Last edition
News about Market
Adaptive Biotechnologies Signs Two Immune Receptor Licensing Deals with Pfizer
Adaptive Biotechnologies has signed two immune receptor licensing agreements with Pfizer, covering a T-Cell Receptor (TCR) discovery collaboration in rheumatoid arthritis and access to Adaptive’s proprietary TCR-antigen datasets for immunology R&D.
Market | 16/12/2025 | By News Bureau | 222
Dyadic Applied BioSolutions has entered into a commercial partnership with Opes to accelerate adoption of its recombinant growth factors and media proteins, leveraging Opes’ market presence in Europe, Israel and Asia, while retaining Dyadic’s ability to sell directly and engage additional partners, globally.
Market | 16/12/2025 | By News Bureau | 107
ADEL Signs USD 1.04 Billion Global Licensing Deal with Sanofi for Alzheimer's Drug
ADEL has signed a global licensing deal with Sanofi for its investigational Alzheimer’s therapy ADEL-Y01, valued at up to USD 1.04 billion, including a USD 80 million upfront payment, milestone payments and royalties.
Market | 16/12/2025 | By News Bureau | 131
Viva Biotech-Backed Arthrosi Enters USD 1.5 Billion Acquisition Deal with Sobi
Biovitrum AB (Sobi) has entered into an acquisition agreement with Viva Biotech–backed Arthrosi Therapeutics, with a total deal value of up to USD 1.5 billion, including USD 950 million upfront and up to USD 550 million in contingent payments, subject to closing in the first half of 2026.
Market | 16/12/2025 | By News Bureau | 160
Akums Launches Enhanced Gabapentin ER Formulation for PHN
Akums Drugs and Pharmaceutical has introduced an enhanced Gabapentin Extended-Release (ER) formulation powered by its RetenEx technology for the management of postherpetic neuralgia (PHN), a chronic neuropathic pain condition that affects around 10-20 percent of patients following a shingles outbreak.
Market | 15/12/2025 | By News Bureau | 152
Biocon Launches its Glucagon-like Peptide-1 (GLP -1), Liraglutide in Netherlands
Biocon has launched its GLP-1 drug–device combination, Liraglutide, in the Netherlands, where it will be marketed under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.
Market | 15/12/2025 | By News Bureau | 190
Senores Pharma Wins US FDA Approval for Deferiprone Tablets, Launched by Dr Reddy's
Senores Pharmaceuticals has announced the approval and US launch of Deferiprone Tablets USP (500 mg and 1000 mg), to be marketed by Dr Reddy’s Laboratories Inc.
Market | 15/12/2025 | By News Bureau | 186
Gaelic Laboratories Strengthens Manufacturing Footprint with Acquisition of Athlone Laboratories
Gaelic Laboratories, an Ireland-based manufacturer of beta-lactam (penicillin) products established in 2022, has acquired Athlone Laboratories, a long-standing developer and manufacturer of oral-dose beta-lactam medicines.
Market | 14/12/2025 | By Darshana | 144
Orphalan announces acquisition of Orphelia Pharma
Orphalan has strengthened its leadership in rare diseases with the acquisition of Orphelia Pharma, expanding its global footprint and enhancing its portfolio of treatments for severe paediatric neurological and oncological conditions.
Market | 12/12/2025 | By Akanki | 214
Platform Technologies Drive USD 211 Billion Surge in Precision Cancer Treatment
The rapid rise of platform technologies has added USD 211 billion in value to the precision oncology landscape, with immunotherapies now accounting for more than 45 percent of global anticancer drug revenues—underscoring strong investor confidence in biologically targeted treatment approaches.
Market | 12/12/2025 | By Akanki | 147
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy